4.6 Article

Extranodal extension is a criterion for poor outcome in patients with metastatic nodes from cancer of the nasopharynx

Journal

ORAL ONCOLOGY
Volume 88, Issue -, Pages 124-130

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.oraloncology.2018.11.007

Keywords

Extranodal extension; Nodal staging; Head and neck cancers; Nasopharyngeal cancer; Magnetic resonance imaging

Funding

  1. Research Grants Council of the Hong Kong Special Administrative Region, China [SEG_CUHK02]

Ask authors/readers for more resources

Purpose: Extranodal extension (ENE) is a criterion for advanced nodal staging of oropharyngeal and hypopharyngeal carcinoma. Our aim was to determine if ENE should be a staging criterion for nasopharyngeal carcinoma (NPC). Materials & methods: MRI of 546 NPC patients were reviewed retrospectively and in 404/546 (74.0%) with metastatic nodes, the nodes were assessed for ENE (grade 0 = absent; grade 1 = infiltration of surrounding fat; grade 2 = infiltration of muscle/skin), size (total volume), site (unilateral/bilateral and upper/lower neck) and necrosis. Associations between nodal features and regional relapse free survival (RRFS), distant metastases free survival (DMFS) and overall survival (OS) were assessed using cox regression. Differences of survival rates were compared using log-rank test. A p-value of < 0.05 indicates statistical significance. Results: ENE grade was the only determinant of RRFS (p = 0.014) and only independent determinant of DMFS (p = 0.003) and OS (p < 0.001). Grade 2 ENE was associated with significantly poorer RRFS, DMFS and OS compared to grade 0 and 1 (p < 0.05). Addition of grade 2 ENE to N1 and N2 disease showed similar poor RRFS, DMFS and OS to N3 disease (p > 0.05). Compared to the current stage N3 disease, inclusion of grade 2 ENE increased the number of N3 patients from 53/546 (9.7%) to 82/546 (15.0%) with similar hazard ratios for DMFS (6.855 and 7.125, respectively) and OS (3.614 and 4.085, respectively). Conclusion: Grade 2 ENE (into muscle and/or skin and/or salivary glands) is an independent indicator of poor outcome and may be considered as a new criterion for N3 nodal disease in NPC.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Radiology, Nuclear Medicine & Medical Imaging

Discriminating between benign and malignant salivary gland tumors using diffusion-weighted imaging and intravoxel incoherent motion at 3 Tesla

Rongli Zhang, Ann D. King, Lun M. Wong, Kunwar S. Bhatia, Sahrish Qamar, Frankie K. F. Mo, Alexander C. Vlantis, Qi Yong H. Ai

Summary: This study retrospectively evaluated the diagnostic performances of diffusion-weighted imaging (DWI) and intravoxel incoherent motion (IVIM) for distinguishing between benign and malignant salivary gland tumors (SGTs). Significant differences in ADC(mean), D-mean, and D*(mean) were found between SGTs. IVIM showed higher accuracy than DWI in discriminating between benign and malignant SGTs due to its advantage in detecting Warthin's tumors (WTs).

DIAGNOSTIC AND INTERVENTIONAL IMAGING (2023)

Article Oncology

Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial

A. T. C. Chan, V. H. F. Lee, R-L Hong, M. -J. Ahn, W. Q. Chong, S. -B. Kim, G. F. Ho, P. B. Caguioa, N. Ngamphaiboon, C. Ho, M. A. S. A. Aziz, Q. S. Ng, C. -J. Yen, N. Soparattanapaisarn, R. K. -C Ngan, S. K. Kho, M. L. A. Tiambeng, T. Yun, V. Sriuranpong, A. P. Algazi, A. Cheng, E. Massarelli, R. F. Swaby, S. Saraf, J. Yuan, L. L. Siu

Summary: Pembrolizumab showed robust antitumor activity and manageable safety in patients with platinum-pretreated recurrent and/or metastatic nasopharyngeal carcinoma. However, it did not significantly improve overall survival compared with chemotherapy.

ANNALS OF ONCOLOGY (2023)

Article Oncology

Recommendations for Epstein-Barr virus-based screening for nasopharyngeal cancer in high- and intermediate-risk regions

W. K. Jacky Lam, Ann D. King, Jacob A. Miller, Zhiwei Liu, Kelly J. Yu, Melvin L. K. Chua, Brigette B. Y. Ma, Ming Yuan Chen, Benjamin A. Pinsky, Pei-Jen Lou, John K. S. Woo, Wan-Lun Hsu, Julia Simon, Denise L. Doolan, Tim Waterboer, Edwin P. Hui, Hui Li, Raymond K. Tsang, Kenneth C. W. Wong, Julian P. Goh, Alexander C. Vlantis, Qi Yong Ai, Lun M. Wong, Victor Abdullah, Jin Ching Lin, Chien-Jen Chen, Ruth M. Pfeiffer, Quynh-Thu Le, Anne W. M. Lee, Mingfang Ji, Sumei Cao, Jun Ma, Anthony T. C. Chan, K. C. Allen Chan, Allan Hildesheim

Summary: A meeting of experts in November 2021 discussed the performance and cost-effectiveness of EBV-based approaches for screening early stage nasopharyngeal carcinoma. Both serum EBV antibody and plasma EBV DNA testing methods were found to be favorable. Additionally, the use of MRI was recommended to increase the sensitivity of NPC detection without greatly impacting the cost-effectiveness of the screening program.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2023)

Review Medicine, General & Internal

Current Applications of Deep Learning and Radiomics on CT and CBCT for Maxillofacial Diseases

Kuo Feng Hung, Qi Yong H. Ai, Lun M. Wong, Andy Wai Kan Yeung, Dion Tik Shun Li, Yiu Yan Leung

Summary: The increasing use of CT and CBCT in oral and maxillofacial imaging has led to the development of deep learning and radiomics applications for maxillofacial disease diagnosis and management. Deep learning models have been developed for automatic diagnosis, segmentation, and classification of various maxillofacial diseases, while radiomics applications mainly focus on diagnosing occult metastasis and osteoarthritis. These models show high performance and have the potential for clinical use, but challenges in generalizability and reproducibility need to be addressed.

DIAGNOSTICS (2023)

Article Biochemistry & Molecular Biology

A novel tumor suppressor encoded by a 1p36.3 lncRNA functions as a phosphoinositide-binding protein repressing AKT phosphorylation/activation and promoting autophagy

Lili Li, Xing-sheng Shu, Hua Geng, Jianming Ying, Lei Guo, Jie Luo, Tingxiu Xiang, Longtao Wu, Brigette B. Y. Ma, Anthony T. C. Chan, Xiaofeng Zhu, Richard F. Ambinder, Qian Tao

Summary: Peptides/small proteins encoded by noncanonical open reading frames (ORF) of previously claimed non-coding RNAs have important biological functions but are largely uncharacterized. In this study, we identified and validated a small protein SP0495 as a novel tumor suppressor, frequently inactivated by promoter methylation in multiple tumors. SP0495 functions as a phosphoinositide-binding protein, regulating AKT signaling activation and autophagy. It inhibits tumor cell growth and induces apoptosis, cell cycle arrest, senescence, and autophagy through multiple mechanisms, including the modulation of phosphoinositides turnover and autophagic/proteasomal degradation of autophagy regulators. SP0495 has the potential to be a biomarker for cancer diagnosis and prognosis.

CELL DEATH AND DIFFERENTIATION (2023)

Article Multidisciplinary Sciences

Fragmentation landscape of cell-free DNA revealed by deconvolutional analysis of end motifs

Ze Zhou, Mary-Jane L. Ma, Rebecca W. Y. Chan, W. K. Jacky Lam, Wenlei Peng, Wanxia Gai, Xi Hu, Spencer C. Ding, Lu Ji, Qing Zhou, Peter P. H. Cheung, Stephanie C. Y. Yu, Jeremy Y. C. Teoh, Cheuk-Chun Szeto, John Wong, Vincent W. S. Wong, Grace L. H. Wong, Stephen L. Chan, Edwin P. Hui, Brigette B. Y. Ma, Anthony T. C. Chan, Rossa W. K. Chiu, K. C. Allen Chan, Y. M. Dennis Lo, Peiyong Jiang

Summary: Using a non-negative matrix factorization algorithm, this study identified distinct types of cfDNA cleavage patterns based on different end motifs. These profiles were associated with specific DNA nucleases and could be used to diagnose autoimmune disorders and cancer.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2023)

Article Oncology

Frequency of Peripheral CD8+T Cells Expressing Chemo-Attractant Receptors CCR1, 4 and 5 Increases in NPC Patients with EBV Clearance upon Radiotherapy

Shweta Mahajan, Hayri E. Balcioglu, Astrid Oostvogels, Willem A. Dik, K. C. Allen Chan, Kwok-Wai Lo, Edwin P. Hui, Anna Tsang, Joanna Tong, Wai Kei Jacky Lam, Kenneth Wong, Anthony T. C. Chan, Brigette B. Y. Ma, Reno Debets

Summary: Post-radiotherapy clearance of plasma EBV DNA is associated with prognosis in NPC patients. T cells, particularly CD8+ T cells expressing CCR1, 4 and/or 5, play a role in this clearance process. Differences in chemo-attractants related to T-cell chemotaxis are also linked to clinical outcome. Validation in larger cohorts is needed to confirm these findings.

CANCERS (2023)

Article Medicine, General & Internal

Long-term Outcomes of Bevacizumab and Chemoradiation for Locoregionally Advanced Nasopharyngeal Carcinoma: A Nonrandomized Controlled Trial

Nancy Y. Lee, Jonathan Harris, John Kim, Adam Garden, James Mechalakos, David G. Pfister, Anthony T. C. Chan, Kenneth Hu, A. Dimitrios Colevas, Steven Frank, George Shenouda, Voichita Bar-Ad, John N. Waldron, Paul M. Harari, Adam Raben, Pedro Torres-Saavedra, Quynh-Thu Le

Summary: The study aimed to assess the long-term toxic effects and clinical outcomes associated with adding bevacizumab, a vascular endothelial growth factor inhibitor, to standard chemoradiation for patients with nasopharyngeal carcinoma (NPC). The results showed favorable long-term outcomes and no severe adverse events when using bevacizumab in combination with chemoradiation. Further investigation may be warranted.

JAMA NETWORK OPEN (2023)

Article Oncology

Nasopharyngeal cancer screening with an anti-BNLF2b antibody: a new arrow in the quiver?

W. K. Jacky Lam, Anthony T. C. Chan

Summary: A recent study has identified a new serological biomarker for NPC screening that targets the EBV protein BNLF2b. This biomarker demonstrated higher sensitivity and specificity for NPC detection compared with conventional antibodies.

NATURE REVIEWS CLINICAL ONCOLOGY (2023)

Review Oncology

Radiomics Analysis in Characterization of Salivary Gland Tumors on MRI: A Systematic Review

Kaijing Mao, Lun M. Wong, Rongli Zhang, Tiffany Y. So, Zhiyi Shan, Kuo Feng Hung, Qi Yong H. Ai

Summary: This study systematically evaluated the procedures of radiomics analysis for characterizing salivary gland tumors (SGTs) on MRI. Radiomics analysis showed potential in characterizing SGTs on MRI, but its clinical application is limited due to complex procedures and a lack of standardized methods. This review summarized the procedures of radiomics analysis, focusing on reported methodologies and performances, and proposed potential standards for further development, which may benefit the application of radiomics analysis in characterizing SGTs on MRI.

CANCERS (2023)

Article Oncology

Role of chemotherapy in patients with nasopharynx carcinoma treated with radiotherapy (MAC-NPC): an updated individual patient data network meta-analysis

Claire Petit, Anne Lee, Jun Ma, Benjamin Lacas, Wai Tong Ng, Anthony T. C. Chan, Ruey-Long Hong, Ming-Yuan Chen, Lei Chen, Wen-Fei Li, Pei-Yu Huang, Terence Tan, Roger K. C. Ngan, Guopei Zhu, Hai-Qiang Mai, Edwin P. Hui, George Fountzilas, Li Zhang, Alexandra Carmel, Dora L. W. Kwong, James Moon, Jean Bourhis, Anne Auperin, Jean-Pierre Pignon, Pierre Blanchard

Summary: This study updated the evaluation of chemotherapy for nasopharynx carcinoma through a network meta-analysis. The results showed that the addition of induction chemotherapy or adjuvant chemotherapy to chemoradiotherapy improved overall survival for patients with non-metastatic nasopharyngeal carcinoma compared to chemoradiotherapy alone.

LANCET ONCOLOGY (2023)

Article Medicine, General & Internal

Evaluation of contemporary olanzapine- and netupitant/palonosetron-containing antiemetic regimens for chemotherapy-induced nausea and vomiting

Christopher C. H. Yip, L. Li, Thomas K. H. Lau, Vicky T. C. Chan, Carol C. H. Kwok, Joyce J. S. Suen, Frankie K. F. Mo, Winnie Yeo

Summary: This retrospective analysis compared the efficacy of olanzapine-based and NEPA-based regimens in controlling chemotherapy-induced nausea and vomiting (CINV) in breast cancer patients receiving AC. The olanzapine group showed higher rates of no rescue therapy and no significant nausea during cycle 1 of AC. However, there were no differences in quality of life between the two groups. Multiple cycle assessment revealed higher rates of total control in the NEPA group in later cycles. These results do not support the superiority of either regimen for breast cancer patients receiving AC.

HONG KONG MEDICAL JOURNAL (2023)

Article Oncology

Long-term outcomes of neo-adjuvant chemotherapy on borderline resectable oral cavity cancers: Real-world data of 3266 patients and implications for clinical practice

Vanita Noronha, Aditya Dhanawat, Vijay Maruti Patil, Nandini Menon, Ajay Kumar Singh, Pankaj Chaturvedi, Prathamesh Pai, Devendra Chaukar, Sarbani Ghosh Laskar, Kumar Prabhash

Summary: Neo-adjuvant chemotherapy has shown long term survival benefits in patients with locally advanced oral cavity squamous cell carcinomas.

ORAL ONCOLOGY (2024)

Article Oncology

Development of machine learning models for the prediction of long-term feeding tube dependence after oral and oropharyngeal cancer surgery

Andrea Costantino, Claudio Sampieri, Gian Marco Pace, Bianca Maria Festa, Luca Cerri, Giorgio Gregory Giordano, Michael Dale, Giuseppe Spriano, Giorgio Peretti, Armando De Virgilio

Summary: This study aimed to predict the necessity of enteral nutrition at 28 days after surgery in patients with head and neck cancers. The results showed that the machine learning models had optimistic accuracy in predicting the need for enteral nutrition, but had moderate sensitivity.

ORAL ONCOLOGY (2024)

Article Oncology

Comprehensive clinical, genome and transcriptomic analysis of primary ghost cell odontogenic carcinoma

Lirui Zhang, Qiaoshi Xu, Zhien Feng

Summary: This study presents a comprehensive clinical, genomic, and transcriptomic analysis of primary ghost cell odontogenic carcinoma (GCOC). The results provide the first comprehensive molecular atlas for primary GCOC, including previously identified CTNNB1 mutation and novel alterations in MAP3K, EP300, and the 22q11.21 region. The transcriptome analysis reveals significant involvement of cytokine-cytokine receptor interaction and the PI3K-Akt signaling pathway. More GCOC cases should be compared to validate these findings for accurate clinical guidance.

ORAL ONCOLOGY (2024)

Article Oncology

Anti-LGALS3BP antibody-drug conjugate treatment induces durable and potent antitumor response in a preclinical model of adenoid cystic carcinoma

Emily Capone, Vittoria Perrotti, Ilaria Cela, Rossano Lattanzio, Lucrezia Togni, Corrado Rubini, Vito Carlo Alberto Caponio, Lorenzo Lo Muzio, Martina Colasante, Francesco Giansanti, Rodolfo Ippoliti, Stefano Iacobelli, Michael J. Wick, Nicole Spardy Burr, Gianluca Sala

Summary: This study explores the potential of galectin-3 binding protein (LGALS3BP) as a novel target for antibody-drug conjugate (ADC) therapy in adenoid cystic carcinoma (ACC). The results show that LGALS3BP is highly expressed in ACC tissues and treatment with anti-LGALS3BP ADC leads to durable tumor growth inhibition in animal models.

ORAL ONCOLOGY (2024)

Article Oncology

Transoral robotic surgery in oropharyngeal squamous cell carcinoma: A comparative study between da Vinci Single-Port and da Vinci Xi systems

Andrea Costantino, Claudio Sampieri, Piero Giuseppe Meliante, Armando De Virgilio, Se-Heon Kim

Summary: This study compares the outcomes of transoral resections using the da Vinci SP and da Vinci Xi systems for oropharyngeal squamous cell carcinoma (OPSCC). The results indicate that the da Vinci SP system has advantages in terms of reduced docking and console times, as well as improved rates of wide negative resection margins. However, there were no significant differences in complication rates or postoperative functional outcomes between the two systems.

ORAL ONCOLOGY (2024)